low_ JAJP.qxd

Size: px

Start display at page:

Download "low_ JAJP.qxd"

しゅんすけさかど
4 years ago
Views:

1 LC/MS Chad Borges, Matthew Slawson, James Taccogno, and Dennis Crouch Center for uman Toxicology University of Utah Salt Lake City, UT USA John M. ughes Agilent Technologies, Inc. Pleasanton, CA USA (oa-tof) Agilent LC/MSD TOF 1 2 ng/ml 4 1 TOF (2 ppm ) (EIC) LC/MSD TOF EIC 1.8 C18 [1 3] ( BALCO TG ) / (GC/MS) [2] EI GC/MS [4] GC/MS [5] GC/MS GC/MS GC/MS (SRM) (MRM) / (LC/MS) [6]

2 API LC/MS 40 GC/MS LC/MS [7] 2 -ng/ml [ (WADA) (MRPL)] WADA MRPL Agilent LC/MSD TOF 1 (ISTD) (ESI) APCI APCI ESI (Na + K + ) APCI 1 APCI ESI O Cl 2 N Cl N 3 C C 3 C 3 O Clenbuterol 19-norandrosterone N N 3 C 3 C C 3 O C 3 O C 3 3'- stanozolol 3 C 3 C Methyltestosterone (internal standard) Methyltestosterone metabolite (17α-methyl-5β-androstane-3α,17β-diol) C 3 O O Epitestosterone Epimetendiol (methandrostenolone metabolite) 1. 2

3 [M+] + m/z ( P-921) LC MS APCI 1 GC/MS the Center for uman Toxicology, Sports Medicine Research and Testing Laboratory LC/MS GC/MS 3 ml (10 ng/µl 20 µl) 0.15 M 1mL p 5 Extrelut-3 (MerckVMR ) 1 g SPE (J.T.Baker VMR J ) 8 9 ml 13 x 100 mm LC/MS 40 Agilent laboratory (Pleasanton, CA) µl LC LC/MS API-TOF Agilent 1100 LC ( UV-VIS ) G1969A LC/MSD TOF ESI APCI Agilent 1. LC : Agilent ZORBAX RRT SB-C mm 1.8 µm (Agilent ) : A = 0.1% / B = : 0.4 ml/min : 55 ºC : 55% B 5 55% 75% B (5 9 ) : 14 : 5 : 4 µl MS : APCI () : 3,500 V : 450 ºC : 4 µa : : 60 psig 5 L/min : 350 ºC : : : : LC/MS m/z ,000 / (0.89 /) (5 µl/min 10 µm ) 150 V [ (CID) ] 60 V ( ) RF: 250 V ( ) 3

4 API-TOF LC/MS GC/MS LC/MS m/z 7,000 2 ppm MRM-MS/MS MS/MS / () ESI 2 ppm [M+] + m/z APCI APCI APCI ESI (Na + K + ) 2 (3 ml 16 ng/ml ) 15 / Base Peak Chrom. of +TOF MS: from steroid2tofap42.wiff Intensity, cps 1.3e5 1.2e5 1.1e5 1.0e5 9.0e4 8.0e4 7.0e4 6.0e4 5.0e4 4.0e4 3.0e4 2.0e4 1.0e Clenbuterol 3 stanozolol Epitestosterone MeTestosterone (IS) Time, min norandrosterone MeTestosterone metabolite Epimetendiol ( 16 ng/ml ()) 4

5 (CID) CID 50V LC/MSD TOF 3 APCI [M+] + [M+-18] + [M+] ppm 3 [M+] + 6,890 [M+] + m/z C m/z (R)m/z (FWM w 1/2 Da) R = M/w 1/2 M = M ( ) w 1/2 = Da R = /0.042 = C [M+] + Intensity, counts 1.10e5 1.00e5 9.00e4 8.00e4 7.00e4 6.00e4 5.00e4 4.00e4 3.00e4 2.00e4 1.00e TOF MS: to min from steroid2tofap42.wiff Agilent, subtracted (4.696 to Epitestosterone, MW 288, Expected (M+) Observed (M+) Mass accuracy (mass error) = (mass obs _ massexp )/mass exp ) 10 6 ( _ )/ ) 10 6 = _ 1.04 ppm Max. 1.2e5 counts. +TOF MS: to min from steroid2tofap42.wiff m/z, amu Intensity, counts 1.10e5 1.00e5 9.00e4 8.00e4 7.00e4 6.00e4 5.00e4 4.00e4 3.00e4 2.00e4 1.00e Max. 1.2e5 counts. Resolution 6890 [(m/z)/w 1/2 ] m/z, amu 3. APCI TOF [M+] + = m/z

6 (m/z 271 ) 19- [ 4] m/z ESI LC T MS 2 P-921 (Agilent API ) LC/MSD TOF 5.0e4 4.5e4 4.0e4 +TOF MS: to min from steroid2tofap42.wiff Agilent, subtracted (7.374 to Observed (M+ _ 2 2 O) + m/z 241 Resolution 6403 _ 0.73 ppm 19-norandrosterone, MW e Intensity, counts 3.0e4 2.5e4 2.0e4 Ref mass 8000 counts Observed (M+ _ 2 O) + m/z 259 Resolution 6464 _ 2.86 ppm 1.5e4 1.0e Ref mass 8000 counts m/z, amu m/z

7 19-50 ng/ml ISTD 66 ng/ml 5 3' - (EIC) Base Peak Chrom. of +TOF MS: from steroid2tof wiff Intensity, counts 3.0e6 2.8e6 2.6e6 2.4e6 2.2e6 2.0e6 1.8e6 1.6e6 1.4e6 1.2e6 1.0e6 8.0e5 6.0e5 4.0e5 2.0e Epitestosterone+IS 19-norandrosterone MeTestosterone metabolite Epimetendiol Time, min ng/ml 7

8 2 ng/ml 19-1 ng/ml (MRPL) EIC 6 EIC 50, ,000 S/N EIC TOF EIC 1 mda ( 3 ppm) [M O] + EIC TOF S/N ng/ml(19-1 ng/ml) EIC (1 mda ) 8

9 6 7 TOF 100% 240 pg ( pg) 2 ppm (IS): ppm : 1.59 ppm 19- : 1.99 ppm : 1.84 ppm : 1.78 ppm 7. 2 ng/ml (19-1 ng/ml) ( 240/120 pg) [ 6 ] 9

10 LC/MSD TOF 19- ( 3 ml 0.16 ng/ml ) 20 pg 4 µl (1 mda ) EIC 8 S/N 1.8 -µm 3.5 -µm 1.8 -µm ng/ml ( 20 pg) EIC (1 mda ) 10

11 GC/MS () API-TOF LC/MS 1 2 ng/ml LC/MSD TOF EIC S/N 100 µl 4 µl 1 EIC (m/z 1 mda EIC) ng/ml 2 ppm 1. A. Leinonen, T. Kuuranne, T. Kotiaho, and R. Kostiainen, Screening of unconjugated anabolic steroids in urine by liquid chromatography/ mass spectrometry. In W. Schanzer,. Geyer, A. Gotzmann, and U. Mareck, Recent advances in doping analysis. (2003) Sport und Buch Straub, Koln, 11, Pereira, M. Marques, I. Talhas, and F. Neto, Analysis of androgenic steroids, beta-2-agonists and other substances by GC-MS-ITD. In W. Schanzer,. Geyer, A. Gotzmann and U. Mareck, Recent advances in doping analysis. (2003) Sport und Buch Straub, Koln, 11, T. uynh, G. Trout, and R. Kazlauskas, The detection of low level anabolic agents in bovine and human urine using LC-ESI-MS-MS. In Recent advances in doping analysis. (2003) Sport und Buch Straub, Koln, 11, G. Trout, S. Soo, and R. Kazlauskas, Single screen for steroids using RMS. In Recent advances in doping analysis, (2003) Sport und Buch Straub, Koln, 11, I. Ojanpera, A. Pelander, S. Laks, M. Gergov, E. Vouri and M. Witt, Application of accurate mass measurement to urine drug screening. (2005) J Anal Tox, 29, L. Politi, A. Groppi, and A. Polettini, Application of liquid chromatography-mass spectrometry in doping control. (2005) J Anal Tox, 29, M. Gergov, I. Ojanpera and E. Vuori, Simultaneous screening for 238 drugs in blood by liquid chromatography-ionspray tandem mass spectrometry with multiple reaction monitoring. (2003) J Chrom B, 795, 41. Agilent Technologies, Inc. John ughes Agilent ( 11

12 Agilent Agilent Technologies, Inc Printed in Japan March 20, JAJP

Japanese Journal of Pesticide Science 42(1): (2017)

Japanese Journal of Pesticide Science 42(1): (2017) 42(1), 203 203 215 (2017) DOI: 10.1584/jpestics.W17-54 1, * 2, ** 3, *** 4, **** 4 1 2 3 4 2017 1 6 Recent data analysis technique in mass spectrometry Takaya Satoh, 1 Kentaro Takahara, 2 Tomoaki Kondo,